Is JBIO above its 150-day moving average?

JBIO is currently above its 150-day moving average by 10.39%. The MA150 sits at $16.08.

What is JBIO's RSI right now?

JBIO's 14-period RSI is 16.1. This is in oversold territory (below 30).

Is JBIO's MACD bullish or bearish?

JBIO's MACD histogram reads -0.7981. A negative histogram means short-term momentum is leaning bearish.

How are JBIO's technical signals calculated?

Scanance computes JBIO's technicals daily after market close from end-of-day OHLCV data. MA150 and MA200 are simple moving averages. RSI uses Wilder's 14-period smoothing. MACD uses 12/26/9 exponential moving averages. Volume ratio compares current volume to the 20-day average.

Scanance does not provide investment advice. The technical readouts on this page are pattern matches against deterministic indicator rules — they are not buy or sell recommendations. Always do your own research and consider consulting a licensed financial professional before making any trade.

JB

Jade Biosciences, Inc.

JBIOHealthcareNASDAQ

Biotechnology · Last scanned Jun 3, 2026

PriceMA150MA200

Loading chart…

End-of-day data · ScananceOpen live chart on TradingView ↗

Indicator snapshot · Today

Premium

Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →

Financials · Annual

Revenue

Net Income

-$127.4M

EBITDA

-$113.5M

Scan Results

Daily timeframe

DateIndicatorDetails

About Jade Biosciences, Inc.

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. Valued at $876.1M, JBIO is a small-cap name in its sector. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.

Key stats

Market Cap$876.1M

EPS$-2.63

52W Change+146.2%

Analysis

With $311.3M in cash and $849K in debt, JBIO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating.

With cash comfortably exceeding debt, JBIO has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing JBIO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links

Company website ↗

Jade Biosciences, Inc.

News & analytics is part of Premium.

Technical readouts are part of Premium.